PharmaTutor (September- 2014)
ISSN: 2347 - 7881
(Volume 2, Issue 9)
Received On: 16/06/2014; Accepted On: 27/06/2014; Published On: 01/09/2014
AUTHORS: Rajwinder Rattan*, Tapan Behl, Puneet Sudan, Rashi Wanchoo Misri, Dharmender Jaglan
Department of Applied Sciences,
Doaba Group of Colleges, Kharar, Punjab, India.
*rajwinder.rattan1990@gmail.com
ABSTRACT:
Colorectal is the third most prevalent form of cancer in the world. Several studies report that prostaglandins are mediators of carcinogenesis cyclooxygenase known as prostaglandin endoperoxidase H synthase. Levels of COX-2 isoenzyme and prostaglandins like PGE2, PGF2 alpha and PGE1 are found to be higher in certain cancers like colorectal carcinoma, squamous cell carcinoma of head and neck, also in certain types of breast cancer. Prostaglandins may contribute to the cancer processes through one or more of several mechanism including increased proliferation, apoptosis, enhanced carcinogen metabolism of immune system. Decreasing the high level of COX-2 and prostaglandins already mentioned has shown to decrease carcinogenesis. The understanding of the regulation of substrate availability and of a regulation (Dysregulation in many neoplasis) of the synthesis enzymes has opened avenues leading to design of isoenzyme specific inhibitors and better cancer strategies.
How to cite this article: R Rattan, T Behl, P Sudan, RW Misri, D Jaglan; Biochemistry of Prostaglandins and Cyclooxygenase in Cancer; PharmaTutor; 2014; 2(9); 46-58
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Borne RF: Principles of Medicinal Chemistry, 4th ed. New Delhi: B.I.WaverlyPvt. Ltd., 1999, 535-580.
2. Campbell WB, Halushka PV: Goodman and Gilman's The pharmacological basisof therapeutics, 9th ed. New York: McGraw-Hill, 1996, 601-16.
3. Dubois RN, Abramson SB, Crofford L, Gupta RA, SimonLS, Van De Putte Leo BA,Lipsky PE:Cyclooxigenase in biology and disease.FASEB J1998, 12:1063-73.
4. Marjerus PW: Prostaglandins: Critical roles in pregnancy and colon cancer. CurrBiol1998, 8:87-9.
5. Williams CS, Shattuk-Brandts RL, Dubois RN: The role ofCOX-2 in intestinal cancer. Expert Opin Invest Drugs1999, 8:1-12.
6. Wantanabe T, Satoh H, Togoh M, Taniguchi S, HashimotoY, Kurokawa K:Positive and negative regulation ofcell proliferation through prostaglandin receptor in NIH-3T3 cells. J Cell Physiol1998, 169:401-9.
7. Sharma RA, Gescher AJ, O'Byrne KJ, Steward WP: Familiardrugs may prevent cancer. Postgrad Med J 2001, 77:492-7.
8. Zimmermann KC, Sarbia M, Weber AA, BorchardF,Gabbert HE, Schror K:Cyclooxygenase-2 expressionin human esophageal carcinoma. Cancer Res1999, 59:198-204.
9. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, ColditzGA, Willett WC, Speizer FE:Aspirin and the Risk of ColorectalCancer in Women. N Eng J Med1995, 333:609-14.
10. Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE, Remington PL:Nonsteroidal anti-inflammatory drug useand protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev1996, 5:955-60.
11. Suzuki M, Mori M, Niwa T, Hirata R, Furuta K, Ishikowa T,Noyori R: Chemical implications for anti-tumor and anti-viralprostaglandins: Reaction of D7 -prostaglandin A1andprostaglandin A1methyl esters with thiols. J Am ChemSoc1997, 119:2376-85.
12. Park J, Cho HK, MoonJ: Changes to upper eyelid orbital fat from use of topical bimatoprost. Jpn J Ophthalmol, 2011, 55(1): 22-7.
13. IppolitiC,Pprzepiorka D, Mehra R, Newmann J, Wood J, Claxton D, Gajewskij, Khowi I, van Besien k, Anderson B: Intravesularcarboprost for the treatment of hemorrhagic cystitis after marrow transplantation. Urology 1995, 46(6):811-5.
14. Tari A, Hamada M,Kamiyasu T, SumiiK, Haruma K,Inoue M, Kishimatu S, KajiyamaG, Walsh JH: Effect of enprospil on omeprazole induced hyper gastricnemia and inhibition of gastric acid secretion in peptic ulcer patients.Digestive diseases and sciences 1997, 42(8):1741-6.
15. Bartley J, Brown A, Elton R, Baird DT: Double blind randomised trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion upto 63 days gestation. Human reproduction(Oxford England) 2011, 16(10):2098-102.
16. Goldberg AB, Greenberg MB, Darney PD: Misoprostol and pregnancy. New England Journal of medicine 2011, 344(1): 38-47.
17. Onoe HI, Ueno R, Fujita I, Nishino H, Oomura Y, HayaishiO: Prostaglandin D2Acerebral sleep inducing substance in monkeys.Preceedings of national academy of sciences of United States of America 2012, 85(11):4082-4086.
18. Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G:Rang & Dale’s Pharmacology. Churchill Livingstone Elsevier, 2007.
19. Fischer SM: Prostaglandins and cancer [Reviews:Basic Science]. Front Biosci1997, 2:482-500.
20. Wantanabe T, Nakao A, Emerling D, Hashimoto Y,Tsukamoto K, Kinoshita M, Kurokawa K:Prosataglandin F2a enhancestyrosine phosphorylation and DNA synthesisthrough phospholipase C-coupled receptor via Ca2+-dependantintracellular pathway in NIH-3T3 cells. J BiolChem1994, 269:17619-25.
21. Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R,Daneil VC, Dempsey PJ,Chinery R, Kirkland SC, DuBois RN, Jetton TL, Morrow JD: Epidermal growth factorreceptor activation induces nuclear targeting of cyclooxygenase-2, baso lateral release of prostaglandins and mitogenesisin polarizing colon cancer cells. ProcNatlAcadSci USA1997, 94:657-62.
22. Levy Gerald N: Prostaglandin-H synthase, non steroidalanti-inflammatory drugs and colon cancer. FASEB J1997, 11:234-47.
23. de Bittencourt HPI Jr.,Yane MM, Hirata MH, WilliamsJF: Evidence that prostaglandins modulate lipogenesisincultured lymphocytes-comparison with its effect on macrophagesandtumor cells. BiochemMolBiolInt1994, 33:463-75.
24.Spisni E, Tomasi V: Tumor Angiogenesis 1st ed. NewYork: Oxford University Press, 1997, 291-300.
25. Tsujii M, Kwano S, Dubois RN: Cyclooxygenase-2 expressionin human colon cancer cells increases the metastaticpotential. ProcNatlAcadSci USA1997, 94:3336-40.
26. Masferrer JL, Koki A, Seibert K: COX-2 inhibitors as newclass of anti-angiogenic drugs. Annal N.Y. Acad Sci1999, 889:84-5.
27. Uefuji K, Ichikura T, Mochizuki H: Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesisin human gastric cancer. Clinical Cancer Research 2000,6:135-8.
28. Chiarugi V, Magnelli L, Gallo O: COX-2, iNOS and p53 asplaymakers of tumor angiogenesis. Int J Mol Med1998, 2:715-9.
29. Sawaoka H, Tsuji S, Tsuji M, Gunawan ES, Saski Y,Kawano S, Hori M: COX inhibitors suppress angiogenesisand reduce tumor growth in vivo. Lab Invest 1999, 79:1469-77.
30. Masferrer JL, Leahy K, Zweifl BS, Moore R, HeuvelmanD, Seibert K:Celecoxib: A specific cyclooxygenase(COX-2) inhibitor with antiangiogenic and anticancer activities.Proceedings of the 11th NCI.EORTC.AACRSymposium on New Drugs in Cancer Therapy; 2000 Nov7-10; VrijeUniversiteit, Amsterdam, The Netherlands. ClinicalCancer Research 2000, 6:4486S.
31. Rodrigues S, Nguyen Quang-dé, Faivre S, BruyneelE,Thim L, Westley B, May F, Flatau G, Mareel M, Gespach C, Emami S: Activation of cellular invasion bytrefoil peptides and src is mediated by cyclooxygenaseandthromboxane A2 receptor-dependent signaling pathways.FASEB J 2001,15:1517-28.
32. Rozic JG, Chakraborty C, Lala PK: Cyclooxygenase inhibitorsretard murine mammary tumor progression byreducingtumor cell migration, invasiveness and angiogenesis.Int J Cancer 2001, 93:497-506.
33. Lala PK, Al-Mutter N, Orucevic A: Effects of chronicindomethacin therapy on the development and progressionof spontaneous mammary tumors in C3H/HeJ mice.
Int J Cancer 1997, 73:371-80.
34. Parrett ML, Harris RE, Joarder FS, Ross MS, ClausenKP, Robertson FM: Cyclooxygenase-2 gene expressionin human breast cancer. Int J Oncol1997, 10:503-7.
35. Hida T, Yatabe Y, Achiwa H, Muramatsu H, KozakiK,Nakamura S: Increased expression of cyclo-oxygenasem 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998, 58: 3761-4.
36. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L,Daly JM,Soslow RA, Masferrar JL, Woerner BM, Koki AT, Fahey TJ 3rd: Cyclooxygenase-2 expression is up-regulatedin human pancreatic cancer. Cancer Res 1999, 59:987-90.
37. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, MukaiS,Asai K, Kimura S, Kato H, Kondo M, Hla T: Expression of cyclooxygenase-1 and -2 inhuman colorectal cancer. Cancer Res 1995, 55:2556-9.
38. Baxevanis CN, Reclos GJ, Gritzapis AD, DedousisGVZ,Missitzis I, Papamichail M: Elevated prostaglandin E2production by monocytes is responsible for the depressed levels of natural killer and Lymphokine-activated killer cellfunction in patients with breast cancer. Cancer1993, 72:491-501.
39. Young MR, Young ME, Wepsic HT: Effect of prostaglandinE2 producing nonmetastatic Lewis Lung Carcinoma cellson the migration of prostaglandin E2-responsive metastatic Lewis Lung Carcinoma cells.Cancer Res 1987, 47:3679-83.
40. Tsuji M, Kawano S, Tsuji S, Sawaoka H, Hori M, SawaokaH, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis inducedby colon cancer cells. Cell 1998, 93:705-16.
41. Yamada M, Kawai M, Kawai K, Mashima Y: The effect ofselective cyclooxygenase-2 inhibitor on corneal angiogenesisin the rat. Curr Eye Res 1999, 19:300-4.
42. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL,Woerner B, Edwards DA, Flinckinger AG, Moore RJ, Seibert K:Antiangiogenic and antitumor activitiesof cyclooxygenase-2 inhibitors. Cancer Res 2000, 60:1306-11.
43. Morishita R, Nakamura S, Hayashi Shin-ichiro, TaniyamaY, Moriguchi A, Nagano T, Taiji M, Noguchi H, Takeshita S, Matsumoto K, Nakamura T, Higaki J, Ogihara T: Therapeutic angiogenesisinduced by hepatic growth factor in rabbit hind limbischemia model as cytokine supplement therapy. Hypertension1999, 33:1379-84.
44. Van BE, Witzenbichler B, Chen D, Silver M, Chang L,Schwall R,Isner JM. Potentiated angiogenic effect of scatterfactor/hepatocyte growth factor via induction of vascular endothelial growth factor. The case for paracrine amplificationof angiogenesis.Circulation 1998, 97:381-90.
45. Ota S, Tanaka Y, Bamba H, Kato A, Matsuzaki F:Nonsteroidalanti-inflammatory drugs may prevent colon cancerthrough suppression of hepatocyte growth factor expression. Eur J Pharmacol1999, 367:131-8.
46. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBoisRN: Modulation of apoptosis and Bcl-2 expression byprostaglandin E2 in human colon cancer cells. CancerRes1998, 58:362-6.
47. Chan TA, Morin PJ, Vogelstein B, Kinzler W:Mechanismsunderlyingnonsteroidal anti-inflammatory drugs mediatedapoptosis. ProcNatlAcadSci USA 1998, 95:681-6.
48. Cross DS, Platt JL, John SK, Bach FH, Adams GL:Tumorinfiltrating lymphocytes in squamous cell carcinoma ofhead and neck: Mechanism of enhancement using PGsynthetase inhibitors. AdvExp Med Biol1997, 400:1013-24.
49. Ribas A, Butterfield LH, Economou JS: Genetic immunotherapyfor cancer. The Oncologist 2000, 5:87-98.
50. David SG: The Molecular Perspective: Cyclooxy-genase-2. The Oncologist 2000, 5:169-71.
51. Chinery R, Beauchamp RD, Shyr Yu, Kirkland SC, CoffeyRJ, Morrow JD: Antioxidants reduce COX-2 expression,PG production and proliferation of colorectalcells. Cancer Res 1998, 58:2323-7.
52. Seed MP: Angiogenesis inhibition as a drug target for disease: an update. In. Exp. Opin. Invest. Drugs1996,5: 1617-1637.
53. Needleman P, Turk J, Jakschik BA, Morrison AR Lefkowith JB:Arachidonic acid metabolism. Annu Rev Biochem 1986, 55: 69-102.
54. Taketo M: Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998, 90:1529-1536.
55. Taketo M: Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998, 90:1609-1620.
56. Janne PA, Mayer RJ: Chemoprevention of colorectal cancer. N Engl J 2000, 342:1960-1968.
57. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C:Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991, 101:635-639.
58. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342:1946-1952.
59. Bennett A, Del Tacca M: Proceedings: Prostaglandins in human colonic carcinoma. Gut 1975, 16:409.
60. Jaffe BM: Prostaglandins and cancer: an update. Prostaglandins 1974, 6: 453-461.
61. Reddy BS, Maruyama H,Kelloff G: Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidalantiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987, 47:5340-5346.
62. Steinbach G, Lynch PM, Phillips Robin KS, Wallace MH,Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B, Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman S, Sherman JW, Kelloff G: The Effect of Celecoxib, aCyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis.N Eng J Med 2000, 342:1946-52.
.png)
